BioCentury
ARTICLE | Top Story

Celgene boosts itself, Acceleron

October 24, 2014 2:21 AM UTC

Celgene Corp. (NASDAQ:CELG) added $5.64 (5.9%) to $100.40 on Thursday after reporting adjusted net income of $806 million in 3Q14, up 20% from $669 million in 3Q13, and upped its revenue and EPS guidance for the year.

In the cancer portfolio, global sales of Revlimid lenalidomide were $1.3 billion in 3Q14, up 19% from $1 billion in 3Q13. On the conference call, the company noted near-term events that would drive the thalidomide analog's trajectory, including a Feb. 22, 2015, PDUFA date for use in newly diagnosed multiple myeloma and an opinion from EMA's CHMP for the indication in 1H15. ...